Emerging as a new treatment option in rare and orphan disease areas, oligonucleotides have matured into a drug class with a broad indication spectrum. The promise of oligonucleotides making a difference to an increasing number of patients.
With decades of experience in the development, production and regulatory support of APIs, Bachem is extending its focus from peptides to oligonucleotides which leads overall to a transformation of the organization. As can be expected from Bachem, this transformation is being executed meticulously, with a strong focus on innovation and quality. Our aim is to be the first-choice oligonucleotide manufacturer.
---------------------------------------------------------------------------------------------------------------------------
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Learn more about our products and services at www.bachem.com/
28 авг 2024
